GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (STU:7CB) » Definitions » Total Receivables

Statera BioPharma (STU:7CB) Total Receivables : €0.37 Mil (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Total Receivables?

Statera BioPharma's Total Receivables for the quarter that ended in Sep. 2022 was €0.37 Mil.


Statera BioPharma Total Receivables Historical Data

The historical data trend for Statera BioPharma's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Total Receivables Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Total Receivables
- 0.27 0.31

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.12 0.31 0.26 0.39 0.37

Statera BioPharma Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Statera BioPharma Total Receivables Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Statera BioPharma Business Description

Traded in Other Exchanges
N/A
Address
4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Statera BioPharma Headlines

No Headlines